Propionate Decreases Microglial Activation but Impairs Phagocytic Capacity in Response to Aggregated Fibrillar

Andrew Gold1, Sarah Kaye2, Jie Gao2

  • 1Human Nutrition Program and James Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43210, United States.

ACS Chemical Neuroscience
|October 11, 2024
PubMed

Insights

Propionate, a microbial byproduct, dampens microglial immune responses to amyloid beta in Alzheimer's disease models. However, this beneficial effect on inflammation comes at the cost of reduced microglial phagocytosis, impacting disease pathology.

Area of Science:

  • Neuroimmunology
  • Microbial metabolites
  • Alzheimer's disease pathogenesis

Background:

  • Microglia, the brain's immune cells, play a key role in Alzheimer's disease (AD) by interacting with amyloid beta (Aβ) aggregates.
  • Microglial clearance of Aβ can trigger neuroinflammation, making microglial response modulation critical for AD treatment.
  • Short-chain fatty acids (SCFAs) are microbial metabolites that can cross the blood-brain barrier and influence microglial function.

Purpose of the Study:

  • To investigate the impact of propionate, a representative SCFA, on microglial responses to Aβ in an in vitro model of Alzheimer's disease.

Main Methods:

  • Utilized a multiomics approach (transcriptomics, metabolomics, lipidomics) to analyze immortalized murine microglia.
  • Stimulated microglia with Aβ and assessed Aβ phagocytosis and reactive nitrogen species secretion.
  • Characterized changes in gene expression, metabolite profiles, and lipid composition.

Main Results:

  • Propionate significantly blunted the early inflammatory response of microglia to Aβ, downregulating immune and complement system genes.
  • Reduced expression of Aβ-binding scavenger receptors (e.g., CD36, Msr1) and Apoe, while upregulating inflammation-dampening Lpl.
  • Altered microglial metabolism, affecting phospholipid composition and arginine metabolism, leading to decreased nitric oxide production and impaired phagocytosis.

Conclusions:

  • Propionate modulates microglial immune activation in response to Aβ, potentially offering a therapeutic avenue for AD.
  • The anti-inflammatory effects of propionate may be counterbalanced by impaired microglial phagocytic capacity.
  • Further research is needed to fully elucidate the complex role of propionate in AD pathophysiology.